Literature DB >> 34392955

Incidence and outcomes of malignant ovarian germ cell tumors in Korea, 1999-2017.

Meerim Park1, Jiwon Lim2, Jun Ah Lee1, Hyeon Jin Park1, Byung Kiu Park1, Myong Cheol Lim3, Sang-Yoon Park3, Young-Joo Won4.   

Abstract

OBJECTIVE: Malignant ovarian germ cell tumor (MOGCT) is a rare ovarian malignancy accounting for less than 5% of all ovarian cancers. We aimed to evaluate the incidence, survival, and subsequent malignancies after the diagnosis of MOGCT.
METHODS: Data from the Korea Central Cancer Registry were used to identify MOGCTs between 1999 and 2017. The age-standardized rates (ASRs), 5-year relative survival rates (RSR) and standardized incidence ratio (SIR) for subsequent cancer after diagnosis of MOGCT were estimated.
RESULTS: Of 2125 cases of newly diagnosed MOGCTs, 596 (28.0%) were diagnosed with dysgerminoma and 1529 (72.0%) with non-dysgerminoma. The ASR per 100,000 women-years was 0.539; ASR slightly increased over the study period (annual percent change [APC] = 1.01%; p = 0.02). There was an increase and decrease in the incidence of MOGCTs in the age groups 0-19 years (APC = 1.96%; p < 0.01) and ≥ 50 years (APC = -6.51%; p < 0.01), respectively. Patients with dysgerminoma showed significantly higher RSR than patients with non-dysgerminoma (98.0% vs. 94.9%, p < 0.01). Patients aged ≥50 years showed worst 5-year RSR (68.7%) than patients aged 0-19 years (97.8%) and 20-34 years (96.4%) (p < 0.01). The overall SIR for a subsequent cancer occurrence was 2.07, with the most frequent site of subsequent primary cancer being the thyroid (SIR = 2.78).
CONCLUSIONS: Our data demonstrated an excellent prognosis of MOGCTs among Korean women. There was a slight increase in MOGCT prevalence, which was more pronounced among those aged <19 years. After MOGCT diagnosis, the risk of developing a subsequent malignancy was doubled compared with the general population.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Incidence; Malignant ovarian germ cell tumors; Subsequent cancer; Survival

Mesh:

Year:  2021        PMID: 34392955     DOI: 10.1016/j.ygyno.2021.07.037

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Incidence and Survival Rates for Female Malignant Germ Cell Tumors: An Institutional Review.

Authors:  Afshan Saeed Usmani; Iqra Yasin; Rehan B Asif; Nazish Kahlid; Aamir Syed
Journal:  Cureus       Date:  2022-04-26

Review 2.  Growing Teratoma Syndrome with Synchronous Gliomatosis Peritonei during Chemotherapy in Ovarian Immature Teratoma: A Case Report and Literature Review.

Authors:  Sijian Li; Na Su; Congwei Jia; Xinyue Zhang; Min Yin; Jiaxin Yang
Journal:  Curr Oncol       Date:  2022-09-04       Impact factor: 3.109

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.